Efficacy and Saftey of Intravenous Versus Oral Iron Therapy in Postpartum Anemia - A Randomised Controlled Trial
Phase 4
- Registration Number
- CTRI/2020/02/023125
- Lead Sponsor
- Department of Obstetrics And Gynecology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with Hemoglobin between 8-10gm/dl, 36-48 hours after delivery.
Group A will be treated with Intravenous Iron .
Group B will be treated with Tablet Iron.
Exclusion Criteria
Peripartum Blood Transfusion
Intolerance To Iron Derivatives
Clotting disorders
Patients with Anemia other than that caused by blood loss secondary to delivery and iron deficiency anemia.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To identify the efficacy of Intravenous Iron therapy compared with Oral Iron for treating Postpartum anemiaTimepoint: 36-48 Hours after delivery <br/ ><br>2 Weeks and 6 Weeks Postpartum period
- Secondary Outcome Measures
Name Time Method To find out if there are adverse drug reaction to Intravenous Ferric carboxy maltose as treatment for Postpartum anemia <br/ ><br> <br/ ><br>To find out the acceptability of intravenous iron ( ferric carboxy maltose) therapy for postpartum anemiaTimepoint: 36-48 Hours after delivery <br/ ><br>2 Weeks and 6 Weeks Postpartum period